Advertisement
Loading...

Evolus, Inc.

EOLSNASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$6.50
$-0.08(-1.22%)
U.S. Market opens in 28h 22m

Evolus, Inc. Fundamental Analysis

Evolus, Inc. (EOLS) shows moderate financial fundamentals with a PE ratio of -9.80, profit margin of -14.39%, and ROE of 1.75%. The company generates $0.3B in annual revenue with strong year-over-year growth of 11.61%.

Key Strengths

Cash Position11.75%
PEG Ratio-0.39
Current Ratio2.04

Areas of Concern

ROE1.75%
Operating Margin-9.56%
We analyze EOLS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 107.2/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.

Fundamental Health Score

A
107.2/100

We analyze EOLS's fundamental strength across five key dimensions:

Efficiency Score

Weak

EOLS struggles to generate sufficient returns from assets.

ROA > 10%
-19.68%

Valuation Score

Excellent

EOLS trades at attractive valuation levels.

PE < 25
-9.80
PEG Ratio < 2
-0.39

Growth Score

Moderate

EOLS shows steady but slowing expansion.

Revenue Growth > 5%
11.61%
EPS Growth > 10%
1.23%

Financial Health Score

Excellent

EOLS maintains a strong and stable balance sheet.

Debt/Equity < 1
-5.73
Current Ratio > 1
2.04

Profitability Score

Weak

EOLS struggles to sustain strong margins.

ROE > 15%
174.92%
Net Margin ≥ 15%
-14.39%
Positive Free Cash Flow
No

Key Financial Metrics

Is EOLS Expensive or Cheap?

P/E Ratio

EOLS trades at -9.80 times earnings. This suggests potential undervaluation.

-9.80

PEG Ratio

When adjusting for growth, EOLS's PEG of -0.39 indicates potential undervaluation.

-0.39

Price to Book

The market values Evolus, Inc. at -14.78 times its book value. This may indicate undervaluation.

-14.78

EV/EBITDA

Enterprise value stands at -22.42 times EBITDA. This is generally considered low.

-22.42

How Well Does EOLS Make Money?

Net Profit Margin

For every $100 in sales, Evolus, Inc. keeps $-14.39 as profit after all expenses.

-14.39%

Operating Margin

Core operations generate -9.56 in profit for every $100 in revenue, before interest and taxes.

-9.56%

ROE

Management delivers $1.75 in profit for every $100 of shareholder equity.

1.75%

ROA

Evolus, Inc. generates $-19.68 in profit for every $100 in assets, demonstrating efficient asset deployment.

-19.68%

Following the Money - Real Cash Generation

Operating Cash Flow

Evolus, Inc. generates limited operating cash flow of $-36.96M, signaling weaker underlying cash strength.

$-36.96M

Free Cash Flow

Evolus, Inc. generates weak or negative free cash flow of $-41.75M, restricting financial flexibility.

$-41.75M

FCF Per Share

Each share generates $-0.63 in free cash annually.

$-0.63

FCF Yield

EOLS converts -9.58% of its market value into free cash.

-9.58%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-9.80

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.39

vs 25 benchmark

P/B Ratio

Price to book value ratio

-14.78

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.42

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-5.73

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.04

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

1.75

vs 25 benchmark

ROA

Return on assets percentage

-0.20

vs 25 benchmark

ROCE

Return on capital employed

-0.19

vs 25 benchmark

How EOLS Stacks Against Its Sector Peers

MetricEOLS ValueSector AveragePerformance
P/E Ratio-9.8028.62 Better (Cheaper)
ROE174.92%783.00% Weak
Net Margin-14.39%-48181.00% (disorted) Weak
Debt/Equity-5.730.39 Strong (Low Leverage)
Current Ratio2.044.12 Strong Liquidity
ROA-19.68%-21914.00% (disorted) Weak

EOLS outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Evolus, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

175.06%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

83.42%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

61.78%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ